Brian Piekos - 09 Sep 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Financial Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
09 Sep 2024
Transactions value $
$0
Form type
4
Filing time
11 Sep 2024, 16:34:04 UTC
Previous filing
05 Feb 2024
Next filing
25 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (right to buy) Award $0 +100K $0.00 100K 09 Sep 2024 Common Stock 100K $11.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.